Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 19, 2024 08:30 ET | Source: Kairos Pharma, Ltd.

Kairos Pharma Approved to Dual List on Upstream

LOS ANGELES, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. (KAPA) today announced its approval to dual list its shares on Upstream, a MERJ Exchange market and global securities trading app....
October 22, 2024 09:00 ET | Source: Kairos Pharma, Ltd.

Kairos Pharma to Present at the LD Micro Main Event XVII

LOS ANGELES, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer,...
October 09, 2024 16:30 ET | Source: Kairos Pharma, Ltd.

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

LOS ANGELES, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer,...
September 24, 2024 16:20 ET | Source: Kairos Pharma, Ltd.

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

LOS ANGELES, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces a groundbreaking collaboration with PreCheck Health...
September 17, 2024 16:29 ET | Source: Kairos Pharma, Ltd.

Kairos Pharma Closing of $6.2 Million Initial Public Offering

LOS ANGELES, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. (“Kairos Pharma” or the “Company”) (NYSE American: KAPA), a clinical stage biopharmaceutical company developing cancer...
September 16, 2024 10:49 ET | Source: Kairos Pharma, Ltd.

Kairos Pharma Prices $6.2 Million Initial Public Offering

LOS ANGELES, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. (“Kairos Pharma” or the “Company”), a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse...
January 30, 2024 09:45 ET | Source: Kairos Pharma, Ltd.

Kairos Pharma Doses First Patient in Phase 2 Trial of Lead Drug Candidate ENV105 with Apalutamide to Improve Therapy Sensitivity for Castrate-Resistant Prostate Cancer

LOS ANGELES, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd., a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse cancer drug resistance and immune...
January 16, 2024 09:45 ET | Source: Kairos Pharma, Ltd.

Kairos Pharma Doses First Patients in Phase 1 Trial of Lead Drug Candidate ENV105 with Osimertinib to Improve Therapy Sensitivity for EGFR-Driven Lung Cancer

LOS ANGELES, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd., a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse cancer drug resistance and immune...